tiprankstipranks
Blurbs

Analysts Are Bullish on Top Healthcare Stocks: DENTSPLY SIRONA (XRAY), Veracyte (VCYT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DENTSPLY SIRONA (XRAYResearch Report), Veracyte (VCYTResearch Report) and TG Therapeutics (TGTXResearch Report) with bullish sentiments.

DENTSPLY SIRONA (XRAY)

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on DENTSPLY SIRONA yesterday and set a price target of $65.00. The company’s shares closed last Monday at $54.14.

According to TipRanks.com, CFA is ranked 0 out of 5 stars with an average return of -17.7% and a 37.7% success rate. CFA covers the Healthcare sector, focusing on stocks such as Patterson Companies, AmerisourceBergen, and Oak Street Health.

Currently, the analyst consensus on DENTSPLY SIRONA is a Strong Buy with an average price target of $64.60, a 19.1% upside from current levels. In a report issued on February 18, Robert W. Baird also assigned a Buy rating to the stock with a $67.00 price target.

See today’s best-performing stocks on TipRanks >>

Veracyte (VCYT)

In a report released today, Michael Matson from Needham reiterated a Buy rating on Veracyte, with a price target of $35.00. The company’s shares closed last Monday at $27.80, close to its 52-week low of $22.00.

According to TipRanks.com, Matson is a 4-star analyst with an average return of 7.8% and a 54.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Veracyte has an analyst consensus of Strong Buy, with a price target consensus of $44.00.

TG Therapeutics (TGTX)

In a report released yesterday, Joshua Schimmer from Evercore ISI maintained a Buy rating on TG Therapeutics, with a price target of $20.00. The company’s shares closed last Monday at $9.87, close to its 52-week low of $8.05.

According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 7.6% and a 48.2% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ionis Pharmaceuticals, and Heron Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for TG Therapeutics with a $44.75 average price target, a 351.1% upside from current levels. In a report issued on February 25, H.C. Wainwright also maintained a Buy rating on the stock with a $68.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on XRAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed